Imdevimab

Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (EX-A15458) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .


Cat. No.: EX-A15457	Purity: >98%

	Chemical structure of Imdevimab

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	2250	in-stock
50mg	get quote	in-stock
100mg	get quote	in-stock
500mg	get quote	in-stock
1g	get quote	in-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	REGN10987
CAS No.	2415933-40-1
Purity	>98%
Color	Colorless to light yellow
State	Liquid
Shelf Life	>3 years if stored properly
Storage	Store at -80℃ for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.
Shipping	Shipping with dry ice.

Reference:	[1]. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. [2]. Tada, T., et al., (2021). Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. bioRxiv : the preprint server for biology, 2021.02.18.431897.
CoA	CoA of Imdevimab


		Search